BlackRock Investment Management’s Esperion Therapeutics ESPR Stock Holding History

BlackRock Investment Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$751K	Sell	59,959 -135	-0.2%	-$1.61K	﹤0.01%	2862
2016 Q3	$832K	Sell	60,094 -140	-0.2%	-$1.59K	﹤0.01%	2784
2016 Q2	$595K	Buy	60,234 +15,056	+33%	+$249K	﹤0.01%	2966
2016 Q1	$764K	Buy	45,178 +1,005	+2%	+$16.2K	﹤0.01%	2663
2015 Q4	$983K	Buy	44,173 +285	+0.6%	+$7.19K	﹤0.01%	2618
2015 Q3	$1.03M	Sell	43,888 -683	-2%	-$42.9K	﹤0.01%	2572
2015 Q2	$3.64M	Buy	44,571 +25,103	+129%	+$2.46M	﹤0.01%	1747
2015 Q1	$1.8M	Buy	19,468 +2,362	+14%	+$152K	﹤0.01%	2102
2014 Q4	$692K	Buy	17,106 +3,783	+28%	+$116K	﹤0.01%	2808
2014 Q3	$326K	Sell	13,323 -124	-0.9%	-$1.97K	﹤0.01%	3154
2014 Q2	$213K	Buy	13,447 +69	+0.5%	+$997	﹤0.01%	3228
2014 Q1	$202K	Buy	13,378 +958	+8%	+$14.9K	﹤0.01%	3230
2013 Q4	$171K	Buy	12,420 +756	+6%	+$11K	﹤0.01%	3233
2013 Q3	$220K	Buy	+11,664	New	+$196K	﹤0.01%	3171

Other funds holding ESPR

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock Investment Management's ESPR Position: Q4 2016 in Review

BlackRock Investment Management reduced its Esperion Therapeutics (ESPR) stake by 0.22% in Q4 2016, selling an estimated $1.61K and leaving 59,959 shares worth $751K. The position accounts for ﹤0.01% of the portfolio, ranked #2862.

BlackRock Investment Management first reported a position in ESPR in Q3 2013 and has held it in 14 quarters since. The position peaked at $3.64M in Q2 2015. 99 funds tracked by Wall St. Rank hold ESPR as of Q4 2016.

BlackRock Investment Management held 59,959 shares of Esperion Therapeutics worth $751K as of Q4 2016.
BlackRock Investment Management sold 135 Esperion Therapeutics shares in Q4 2016, an estimated $1.61K.
Esperion Therapeutics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2862 holding.
BlackRock Investment Management first reported a position in Esperion Therapeutics in Q3 2013 and has held it in 14 quarters since.
BlackRock Investment Management's Esperion Therapeutics position peaked at $3.64M in Q2 2015.
99 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.